Does Humana Cover Wegovy?

No. Medicare Part D cannot cover Wegovy — or any drug — for weight loss; this is a federal statutory exclusion that applies to every Medicare plan, including all Humana Part D plans. However, starting July 1, 2026, the Medicare GLP-1 Bridge provides weight-loss access to Wegovy at $50 per month outside Part D. Humana is the CMS-selected processor for that Bridge. Eligibility requirements and exclusions apply — verify with your prescriber.

The Medicare GLP-1 Bridge is a federal program launching July 1, 2026 that gives eligible Medicare beneficiaries access to Wegovy for weight loss at a fixed $50 per month copay through December 31, 2027. It operates outside Part D, so the $50 does not count toward your deductible, TrOOP, or the $2,100 OOP cap. Humana was selected by CMS as the central processor administering the Bridge across all participating plans. Members already on a Part D-covered GLP-1 cannot use the Bridge.

Yes, Medicare Part D can cover Wegovy for cardiovascular risk reduction in adults with established cardiovascular disease who are overweight or obese. Prior authorization is required — your prescriber must document your qualifying CVD diagnosis and BMI. Per-plan formulary tier specifics are not publicly published; verify on the Humana drug-lookup tool. This coverage has been available since the FDA approved the cardiovascular indication in March 2024.

Humana's commercial book is limited, and where it exists, weight-loss Wegovy coverage depends on whether your employer purchased the anti-obesity benefit. If the employer did not include anti-obesity drugs in the benefit design, prior-authorization paperwork will not change that outcome — it is a benefit exclusion, not a medical-necessity denial. ACA individual-market Humana plans generally exclude Wegovy for weight loss. Verify on the plan drug-lookup tool and confirm with your HR department.

Not for Medicare or Medicaid. The NovoCare Wegovy Savings Offer (as little as $25 per month, max $100 savings per 28-day supply) is unavailable to Medicare and Medicaid beneficiaries due to federal anti-kickback rules. Commercially insured Humana members whose plan covers Wegovy may be eligible. ACA exchange and state-employee plans are not treated as government programs for this offer. Verify eligibility at novocare.com.

From January 1, 2027, two pricing changes take effect. Novo Nordisk has announced it will cut Wegovy's list price to approximately $675 per month. Separately, the IRA-negotiated Maximum Fair Price for semaglutide of $274 per 30-day supply also takes effect January 1, 2027. These changes apply to Medicare and, depending on PBM contracting, to commercial plans. Verify current pricing and coverage with Humana or Novo Nordisk.